VistaGen Therapeutics stock analysis
Want to see VTGN full AI Analyst Report?
VistaGen Therapeutics (VTGN) Stock Price & Analysis
VTGN Stock Chart & Stats
- Day’s Range
- $0.16 - $0.19
- 52-Week Range
- $0.16 - $5.14
- Previous Close
- $0.19
- Volume
- N/A
- Average Volume (3M)
- 813.64K
- Market Cap
- $7.56M
- Enterprise Value
- -$5.75M
- Total Cash (Recent Filing)
- $20.03M
- Total Debt (Recent Filing)
- $610.00K
- Price to Earnings (P/E)
- ―
- Beta
- 0.83
- Next Earnings
- Feb 11, 2027 (Est.)
- EPS Estimate
- -0.32
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Path
Constructive FDA feedback gives VistaGen a clearer path for refining fasedienol’s Phase 3 program, reducing uncertainty around endpoint selection and study design. This regulatory alignment can improve development efficiency and strengthen the candidate’s prospects for advancing toward potential approval.
Clinical Tolerability
Long-term extension data showing favorable tolerability across 322 participants supports continued use of fasedienol and may help its clinical positioning. Low adverse-event discontinuation and no serious treatment-attributed events are durable positives for development and adoption potential.
Low Leverage And Gross Margin
Very low debt reduces immediate balance-sheet pressure, while the roughly 78% gross margin indicates the company can generate substantial gross profit on existing revenue. Together, these features leave operating expenses, rather than financing costs or delivery economics, as the primary improvement opportunity.
Bears Say
Sustained Cash Burn
Persistent operating and free-cash-flow losses mean VistaGen is consuming substantial cash to sustain its activities rather than funding them internally. Continued reliance on external financing can constrain strategic flexibility and create recurring funding or dilution pressure over the next several quarters.
Limited Commercial Scale
The company has limited commercial scale relative to its operating cost base, with modest and declining revenue alongside very large operating and net losses. This gap indicates that substantial execution and development progress is still required before the business can approach sustainable profitability.
Shrinking Equity Base
The sharp reduction in equity signals that accumulated losses and/or dilution have materially weakened the capital base. A smaller equity cushion can increase shareholder sensitivity to future financing needs and reduce financial resilience while VistaGen continues funding clinical development.
VistaGen Therapeutics News
VTGN’s Anxiety Study Update Puts Fasedienol in the Investor Spotlight
Vistagen Therapeutics Inc. ($VTGN) announced an update on their ongoing clinical study. Study Overview: The official title of NCT06615557 is “US, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of
VistaGen’s Fasedienol Study Reaches Completion, but Results Remain Pending
Vistagen Therapeutics Inc. ($VTGN) announced an update on their ongoing clinical study. Study Overview: VistaGen’s study is officially titled “A Phase 2, Three-arm, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to
Vistagen selects GATC Health to apply predictive AI to drug development
Vistagen (VTGN) announced its collaboration with GATC Health, a tech-bio company applying artificial intelligence and multiomics to drug discovery and development. The collaboration brings GATC Health’s proprietary Operon platform and
VTGN FAQ
What was VistaGen Therapeutics’s price range in the past 12 months?
What is VistaGen Therapeutics’s market cap?
When is VistaGen Therapeutics’s upcoming earnings report date?
How were VistaGen Therapeutics’s earnings last quarter?
Is VistaGen Therapeutics overvalued?
Does VistaGen Therapeutics pay dividends?
What is VistaGen Therapeutics’s EPS estimate?
How many shares outstanding does VistaGen Therapeutics have?
What happened to VistaGen Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of VistaGen Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
VistaGen Therapeutics
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Shawn K. Singh
- Employees
- 41
- Website
- www.vistagen.com
- Address
- 343 Allerton Avenue, South San Francisco, CA, 94080, US
VistaGen Therapeutics (VTGN) Earnings & Revenues
VTGN Earnings Call
Earnings Call SentimentNeutral
The call presented a balanced mix of progress and uncertainty. Positive elements include completion of PALISADE-3 randomized portion, PALISADE-4 enrollment on track, active open-label extensions, focused operational improvements, an AI/ML-driven analytic program, USAN adoption of refisolone with an IND planned in H1 2026, and $61.8M in reported cash with cost-control measures. Negative elements center on a higher placebo response in PALISADE-3 that necessitates additional analysis and operational remediation, unresolved efficacy clarity from top-line data, potential SAP modifications that would require FDA resubmission, reliance on exploratory AI/ML methods with no guarantees, and limited disclosure on financial runway timing. Given the roughly balanced number of material positives and material uncertainties, the overall tone is cautiously neutral.
View all VTGN earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 15 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 0 | 0 | 12 |












